FDA expands drug to treat NSCLCFDA has extended approval of crizotinib (Xalkori, Pfizer) for the treatment of certain patients with non-small cell lung cancer (NSCLC).
5 things to know about the new lung cancer drugFDA granted accelerated approval to Alecensa (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
Studies: Zykadia shrank tumors in patients with ALK+ NSCLCNew data from two phase 2 studies showed ceritinib (Zykadia) shrank tumors in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who had received previous treatment with an ALK inhibitor and in those receiving an ALK inhibitor for the first time.
Crizotinib better than standard chemotherapy in some patients, study saysIn a phase 3 study of previously treated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), crizotinib (Xalkori, Pfizer) more than doubled median progression free survival (PFS) than when treated with standard chemotherapy, according to a study published June 1, 2013 online in New England Journal of Medicine.
Study confirms low testosterone in crizotinib patientsA new multinational study confirms the impact of the recently-approved lung cancer medication, crizotinib, on testosterone. The study was published online first in the April 12, 2013, issue of Cancer.